Specific therapeutic targeting of epigenetic modifiers has emerged for chromatin reader protein BRD4 for MYC-dependent DLBCL (BET-domain inhibitors) [154], and EZH2 for mainly GCB-type DLBCL [190]. Here, MYC is linked to diffuse large B-cell lymphoma.